1. Herr, H. W., Laudone, V. P., Whitmore, W. F. Jr.: An overview of intravesical therapy for superficial bladder tumors.J. Urol., 138, 1363 (1987).
2. Martinez-Pineiro, J. A., Jimenez-Leon, J. S., Martinez-Pineiro, L. Jr., Fiter, L., Mosteiro, J. A., Navarro, J., Garcia Matres, M. J., Cárcamo, P.: Intravesical therapy comparing BCG, adriamycin and thiotepa in 200 patients with superficial bladder cancer: A randomized prospective study. In: F. M. J. Debruyne, L. Denis, A. P. M. van der Meijden (eds): BCG in Superficial Bladder Cancer. Alan R. Liss. Inc., New York 1989, pp. 237–252.
3. Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, H. B., Stanisic, T. H., Smith, J. A. Jr., Sullivan, J., Sarosdy, M. F., Crissman, J. D., Coltman, C. A.: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional cell carcinoma of the bladder.N. Engl. J. Med., 325, 1205 (1991).
4. Lamm, D. L.: BCG in perspective: Advances in the treatment of superficial bladder cancer.Eur. Urol., 27 (Suppl. 1), 2 (1995).
5. Ganzina, F.: 4′-epi-doxorubicin, a new analogue of doxorubicin: Preliminary overview of preclinical and clinical data.Cancer Treat. Rev., 10, 1 (1993).